A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer. (2nd January 2022)
- Record Type:
- Journal Article
- Title:
- A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer. (2nd January 2022)
- Main Title:
- A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer
- Authors:
- Katanyoo, Kanyarat
Thavorncharoensap, Montarat
Chaikledkaew, Usa
Riewpaiboon, Arthorn - Abstract:
- ABSTRACT: Background: Several instruments are available to measure health utility values. However, limited studies have not yet comprehensively assessed the agreement among these instruments. This study therefore aimed to investigate the performance and agreement of six instruments for utility measures: EQ-5D-3L, EQ-5D-5L (cTTO model), EQ-5D-5L (DCE model), EQ-5D-5L (Hybrid model), TTO, and VAS, among locally advanced cervical cancer (LACC) patients in Thailand. Methods: We compared utility scores derived from six approaches using Friedman's test. We also assessed the agreement of utility scores between each pairwise comparison by intraclass correlation coefficient (ICC) and Bland–Altman plot. Results: The mean (SD) utility values derived from six approaches were as follows: 0.755 ± 0.248 (EQ-5D-3L), 0.801 ± 280 (TTO), 0.806 ± 0.156 (VAS), 0.871 ± 0.184 (cTTO model), 0.875 ± 0.168 (Hybrid model), and 0.900 ± 0.142 (DCE model). Significant differences across six approaches were found in Friedman's test. The ICC showed high agreement between EQ-5D-5L and EQ-5D-3L, and very high agreement between all three models of EQ-5D-5L. The Bland-Altman plots showed wide limit of agreement, except the pairwise comparison, between each model of the EQ-5D-5L. Conclusion: TTO, VAS, EQ-5D-3L and EQ-5D-5L could not be used interchangeably in LACC patients. The impact of using different instruments on economic evaluation findings warrants further investigation.
- Is Part Of:
- Expert review of pharmacoeconomics & outcomes research. Volume 22:Number 1(2022)
- Journal:
- Expert review of pharmacoeconomics & outcomes research
- Issue:
- Volume 22:Number 1(2022)
- Issue Display:
- Volume 22, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 22
- Issue:
- 1
- Issue Sort Value:
- 2022-0022-0001-0000
- Page Start:
- 107
- Page End:
- 117
- Publication Date:
- 2022-01-02
- Subjects:
- Cervical cancer -- utility -- agreement -- EQ-5D -- TTO -- VAS
Pharmacology -- Economic aspects -- Periodicals
338.47615105 - Journal URLs:
- http://www.future-drugs.com/loi/erp ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/14737167.2021.1906224 ↗
- Languages:
- English
- ISSNs:
- 1473-7167
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002996
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 20372.xml